What is the history of Castleman disease?

Castleman disease was first described in 1954 by Dr. Benjamin Castleman, who identified a unique form of localized lymph node hyperplasia in patients. Since then, our understanding of Castleman disease has evolved from viewing it as a single entity to recognizing it as a diverse group of lymphoproliferative disorders with distinct clinical subtypes and underlying inflammatory drivers.

Who first discovered Castleman disease?

In 1954, Dr. Benjamin Castleman published a landmark paper describing a series of patients with localized, benign-appearing lymph node masses. Initially, Castleman disease was thought to be a simple, localized anatomical anomaly. It took decades of clinical observation to distinguish between the localized form (Unicentric) and the more systemic, life-threatening form (Multicentric) that involves multiple organ systems.

How has the understanding of Castleman disease evolved?

The history of Castleman disease is defined by a shift from surgical pathology to molecular immunology. Researchers eventually discovered that Multicentric Castleman disease is often driven by a "cytokine storm," specifically involving the overproduction of Interleukin-6 (IL-6). This realization transformed the condition from a mysterious "tumor-like" growth into a complex inflammatory disorder.

What are the major milestones in the treatment of Castleman disease?

Treatment for Castleman disease has moved away from broad chemotherapy toward targeted precision medicine. Key milestones include:

• 1990s: Initial use of immunosuppressive agents to manage systemic symptoms.


• 2014: FDA approval of siltuximab, a monoclonal antibody specifically designed to block IL-6, revolutionizing care for idiopathic Multicentric Castleman disease.


• Ongoing: Use of antiviral therapies specifically for HHV-8 associated cases.

How has patient advocacy changed the landscape?

The patient experience has been revolutionized by organizations like the Castleman Disease Collaborative Network (CDCN), which empowers patients to participate in research. Today, 59 people with Castleman disease have joined the DiseaseMaps.org community, sharing their unique journeys and helping to bridge the gap between clinical data and lived experience.

Next steps

• Consult with a hematologist-oncologist who specializes in lymphoproliferative disorders.


• Review updated clinical practice guidelines provided by the CDCN to ensure your treatment aligns with current global standards.


• Connect with the 59 members of the DiseaseMaps.org community to share experiences and find support.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Castleman Disease (ORPHA:133)


• Castleman Disease Collaborative Network (CDCN)


• PubMed: "Benjamin Castleman and the History of Castleman Disease"